Compare Summit Therapeutics Inc (SMMT) vs SMX Security Matters plc (SMX) Price & Performance

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.

SMX trades at $3.80, down 2.56% with a bearish technical outlook despite oversold RSI readings. The company shows severe financial distress with no revenue, negative EBITDA of -$130.44M, and deeply negative ROE of -819.22%. Recent news highlights SMX's digital material passport technology gaining media attention from Forbes, TIME, and Boston Herald in September-October 2026, focusing on recycled plastic verification and circular economy applications.

The stock faces substantial fundamental challenges with no current revenue generation and significant operating losses. While media coverage suggests technological potential in material verification, the absence of revenue and massive negative profitability metrics present extreme risk. Investment viability depends entirely on SMX's ability to monetize its technology platform amid ongoing cash burn.